<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335437">
  <stage>Registered</stage>
  <submitdate>3/05/2010</submitdate>
  <approvaldate>6/01/2011</approvaldate>
  <actrnumber>ACTRN12611000011987</actrnumber>
  <trial_identification>
    <studytitle>Stem cells for peripheral vascular disease</studytitle>
    <scientifictitle>Double blind, randomised safety and feasibility evaluation of intra-arterial CD34+ cell delivery for severe peripheral arterial disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral vascular (arterial) disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single dose CD34 cells (at a dose of 3 Ã— 10^5 CD34+ cells per kilogram of recipient's body weight), delivered by intra-arterial infusion, delivered in 20 mls saline over 20 minutes</interventions>
    <comparator>Intra-arterial saline 20ml, delivered over 20 mins</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is the change in ABI (ratio of blood pressure in the arm to ankle). This outcome will be performed by conducting a between groups comparison of the change in ABI from baseline to follow-up.</outcome>
      <timepoint>4 weeks and 3 months following randomization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The secondary outcome is the pain free walk time.  Subjects will be asked to walk at 3km/h on a treadmill at 12 degrees inclination until they develop pain in one or both legs. The test will also be stopped by chest pain or arrhythmia.</outcome>
      <timepoint>4 weeks and 3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life Questionnaire Short Form 36</outcome>
      <timepoint>4 weeks and 3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Transcutaneous oxygen tension in toes</outcome>
      <timepoint>4 weeks and 3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inoperable peripheral arterial disease (PAD) with rest pain or non healing ulcer</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Recent acute coronary disease, severe other life threatening illness</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/01/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Alfred Hospital</primarysponsorname>
    <primarysponsoraddress>Commercial Rd
Melbourne VIC 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council of Australia</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Mitenyi Biotech</sponsorname>
      <sponsoraddress>2 Eden Park Drive. 
North Ryde NSW 2113</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study seeks to establish whether stem cells can be used to treat patients with poor circlation in their legs.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Research and Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>26/04/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof David Kaye</name>
      <address>Heart Centre
Alfred Hospital
Commercial Rd
Melbourne VIC 3004</address>
      <phone>+61 3 9076 3263</phone>
      <fax />
      <email>david.kaye@baker.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bec Stornebrink</name>
      <address>Heart Centre
Alfred Hospital
Commercial Rd
Melbourne VIC 3004</address>
      <phone>+61 3 9076 3263</phone>
      <fax />
      <email>r.stornebrink@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>